ProCE Banner Activity

Phase II BYLieve: Alpelisib Plus Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitor Plus AI

Slideset Download
Conference Coverage
Alpelisib plus fulvestrant demonstrated clinically meaningful efficacy based on the proportion of patients alive without PD at 6 months in this analysis of patients with PIK3CA-mutated HR+/HER2- advanced BC previously treated with CDK4/6i plus AI.

Released: June 03, 2020

Expiration: June 02, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono